Key figures

Telix is a global, commercial-stage biopharmaceutical company focused on the development of diagnostic and therapeutic (‘theranostic’) radiopharmaceuticals.

With more than 20 clinical trials underway worldwide (including partnered investigator-led studies), Telix’s core pipeline aims to address significant unmet medical needs in prostate, kidney, brain, and blood cancers as well as a range of hard to treat immunologic and rare diseases.

Telix’s lead product for prostate imaging has been approved in Australia, Canada, and the United States.

Activities and description

Targeted market

Ongoing projects/partnerships/collaborations